Antibiotic resistance is a growing challenge in the management of infections caused by Gram-negative bacteria. When an organism shows resistance to multiple antibiotics, understanding its susceptibility profile becomes an important part of selecting an appropriate treatment strategy.
Aztreonam-avibactam susceptibility testing is an important topic in antimicrobial research because the combination has complementary activity against certain bacterial resistance mechanisms. However, its activity cannot be assumed for every resistant organism, and laboratory results must be interpreted in the appropriate clinical context.
This article explains how antimicrobial susceptibility testing works, why beta-lactamase mechanisms matter, and how aztreonam-avibactam fits into discussions about resistant Gram-negative bacteria.
What Is Antimicrobial Susceptibility Testing?
Antimicrobial susceptibility testing (AST) is a laboratory process used to evaluate whether a bacterial isolate is susceptible to particular antimicrobial agents under standardized testing conditions.
The results help healthcare professionals understand the activity of different antibiotics against the organism identified in a clinical specimen.
Common susceptibility-testing approaches include:
- Broth microdilution: Measures the minimum inhibitory concentration (MIC) under standardized laboratory conditions.
- Disk diffusion: Evaluates bacterial growth inhibition around an antibiotic-containing disk.
- Molecular testing: Identifies selected resistance genes or genetic markers associated with antimicrobial resistance.
These methods do not provide identical information. Molecular tests can detect specific resistance determinants, while phenotypic susceptibility tests assess the organism’s response to an antimicrobial agent under laboratory conditions.
The appropriate method depends on the organism, antimicrobial agent, validated laboratory procedures and applicable testing standards.
Why Is Aztreonam-Avibactam Susceptibility Important?
Aztreonam and avibactam have different but complementary functions.
Aztreonam is a monobactam beta-lactam antibiotic that interferes with bacterial cell-wall synthesis. Avibactam is a non-beta-lactam beta-lactamase inhibitor that inhibits several susceptible serine beta-lactamases.
Certain resistant Gram-negative bacteria produce multiple beta-lactamases. These enzymes may include metallo-beta-lactamases (MBLs), alongside other enzymes that can compromise the activity of beta-lactam antibiotics.
Aztreonam is relatively stable against hydrolysis by MBLs. However, other beta-lactamases produced by the same organism may still compromise its activity. Avibactam can inhibit several susceptible serine beta-lactamases, helping explain the scientific rationale for combining these agents.
Importantly, avibactam does not directly inhibit MBL enzymes such as NDM, VIM and IMP.
The combination’s activity therefore depends on the organism’s overall resistance mechanisms, susceptibility profile and other relevant factors.
How Do NDM, VIM and IMP Affect Antibiotic Susceptibility?
Metallo-beta-lactamases are enzymes produced by some bacteria that can break down many beta-lactam antibiotics. Three clinically important examples are NDM, VIM and IMP.
1. NDM — New Delhi Metallo-Beta-Lactamase
NDM enzymes can contribute to resistance against several beta-lactam antibiotics, including carbapenems. Their presence can complicate treatment decisions, particularly when additional resistance mechanisms are present.
2. VIM — Verona Integron-Encoded Metallo-Beta-Lactamase
VIM enzymes are another group of MBLs associated with resistance in several Gram-negative bacterial species. Their detection can help characterize the organism’s resistance mechanism, but it does not establish susceptibility to a particular alternative antibiotic.
3. IMP — Imipenemase-Type Metallo-Beta-Lactamase
IMP enzymes can also compromise the activity of multiple beta-lactam antibiotics. As with NDM and VIM, identifying an IMP gene does not replace phenotypic susceptibility testing when that testing is indicated and available.
For all three mechanisms, resistance-gene detection should be interpreted alongside the organism’s identification, laboratory susceptibility results and relevant clinical information.
What Does the Minimum Inhibitory Concentration Mean?
The minimum inhibitory concentration (MIC) is the lowest concentration of an antimicrobial agent that prevents visible bacterial growth under defined laboratory conditions.
MIC results can support susceptibility interpretation when validated methods and applicable interpretive criteria are available.
Three important points should be understood:
- An MIC value must be interpreted using the appropriate organism-specific and drug-specific criteria.
- A numerical MIC should not be interpreted in isolation without considering the testing method and applicable standards.
- Susceptibility results do not guarantee clinical success; infection characteristics and patient-specific factors also matter.
Laboratories should use validated testing procedures and the current interpretive criteria applicable to the antimicrobial agent and organism being evaluated.
Does Detecting an MBL Mean Aztreonam-Avibactam Will Be Active?
No. Detection of an MBL alone does not establish that an organism is susceptible to aztreonam-avibactam.
Although aztreonam has relative stability against MBL-mediated hydrolysis, an organism may produce additional beta-lactamases or possess other resistance mechanisms. These can influence the overall susceptibility profile.
A more complete assessment may include:
- Identification of the bacterial organism.
- Review of relevant resistance mechanisms, where testing is available.
- Antimicrobial susceptibility testing using appropriate laboratory methods.
- Interpretation according to current standards and clinical guidance.
The combination’s activity should not be inferred from a resistance gene alone. Clinical decisions require professional assessment of the complete microbiological and clinical picture.
Aztreonam-Avibactam and Meblanios: Understanding the Difference
Aztreonam-avibactam refers to the combination of two active components. Meblanios is an AIONIOS Pharma product containing aztreonam and avibactam for injection.
Understanding the distinction helps readers separate information about the pharmacology of the generic combination from product-specific information.
Learn more about Meblanios — Aztreonam + Avibactam Injection.
For additional background, read Aztreonam Avibactam: Mechanism of Action and How the Combination Works. This link leads to the AIONIOS Pharma blog listing, where the article can be located.
Product-specific composition, approved indications, administration instructions and other prescribing details should always be confirmed using the applicable approved product information.
The Role of Antimicrobial Stewardship
Susceptibility testing is one part of responsible antimicrobial use. Effective antimicrobial stewardship also involves accurate diagnosis, appropriate specimen collection, infection prevention and the careful interpretation of laboratory results.
Healthcare professionals should consider the complete clinical situation rather than relying on a single resistance marker or laboratory value.
For pharmaceutical researchers and healthcare professionals, understanding the relationship between resistance mechanisms and susceptibility results is essential when evaluating antimicrobial combinations.
Frequently Asked Questions
What is aztreonam-avibactam susceptibility testing?
It refers to laboratory assessment of bacterial susceptibility to the aztreonam-avibactam combination using appropriate, validated methods and applicable interpretive criteria.
Does avibactam directly inhibit NDM, VIM or IMP?
No. Avibactam does not directly inhibit metallo-beta-lactamases. It inhibits several susceptible serine beta-lactamases.
Why is aztreonam relevant to MBL-producing bacteria?
Aztreonam is relatively stable against hydrolysis by MBLs. However, additional beta-lactamases and other resistance mechanisms can affect the organism’s overall susceptibility.
Does the presence of an MBL establish susceptibility to aztreonam-avibactam?
No. The presence of an MBL does not establish susceptibility. Appropriate laboratory testing and interpretation are important.
Is an MIC result enough to predict treatment success?
No. An MIC is a laboratory measurement that must be interpreted using applicable standards. Clinical outcomes depend on additional microbiological, infection-related and patient-specific factors.
Conclusion
Aztreonam-avibactam susceptibility testing is an important subject in the broader study of antimicrobial resistance. Understanding the roles of aztreonam, avibactam and bacterial beta-lactamases helps explain why this combination attracts attention in research on resistant Gram-negative organisms.
However, the presence of an MBL does not automatically establish susceptibility to the combination. Additional resistance mechanisms, validated laboratory testing, applicable interpretive criteria and clinical assessment remain essential.
By understanding these distinctions, healthcare professionals, researchers and pharmaceutical readers can better evaluate the relationship between aztreonam-avibactam, susceptibility testing and antimicrobial resistance.
Medical disclaimer: This article is intended for educational purposes only. It does not replace professional medical advice, approved prescribing information, validated laboratory testing or clinical judgment.